This episode offers a detailed clinical update on the early detection and diagnosis of prostate cancer, tailored for the primary care setting. Dr Bunmi Olajide, a GP with a special interest in cancer services and a Prostate Cancer UK Clinical Champion, presents an evidence-based review of the significant changes to the diagnostic pathway. The discussion highlights how the integration of multi-parametric MRI has led to a 79% reduction in the risk of harm and 90% fewer cases of post-procedure sepsis.

Dr Olajide provides a nuanced analysis of risk stratification, addressing the significant health inequalities that result in a doubled risk for Black men. The discussion covers the clinical application of NICE guidelines, the interpretation of PSA results in the context of confounding factors, and the diminishing role of the DRE as a screening tool. This is an essential briefing for clinicians seeking to align their practice with the latest evidence in prostate cancer management.

Key topics discussed in this episode:

• An overview of the current epidemiology of prostate cancer in the UK.
• A review of key risk factors, including the 1-in-4 lifetime risk for Black men.
• Practical application of the NICE NG12 guidelines and age-specific PSA thresholds.
• The Prostate Cancer Risk Management Programme for managing asymptomatic men.
• The evolution of the diagnostic pathway and the role of multi-parametric MRI.
• A critical appraisal of the digital rectal examination (DRE) in screening for prostate cancer.
• An introduction to the large-scale Transform screening trial, which is examining approaches beyond PSA testing.
• Professional resources and educational opportunities for healthcare professionals.